PMID- 26247816
OWN - NLM
STAT- MEDLINE
DCOM- 20160105
LR  - 20221207
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Linking)
VI  - 86
IP  - 4
DP  - 2015 Oct
TI  - Selective Serotonin Reuptake Inhibitors Plus Phosphodiesterase-5 Inhibitors for 
      Premature Ejaculation: A Systematic Review and Meta-analysis.
PG  - 758-64
LID - S0090-4295(15)00709-8 [pii]
LID - 10.1016/j.urology.2015.06.045 [doi]
AB  - OBJECTIVE: To evaluate the efficacy and safety of combination therapy with 
      selective serotonin reuptake inhibitors (SSRIs) and phosphodiesterase-5 (PDE-5) 
      inhibitors for the treatment of premature ejaculation (PE). METHODS: A systematic 
      search of EMBASE, MEDLINE, the Cochrane Central Register of Controlled Trials, 
      and the Cochrane Database of Systematic Reviews was undertaken to identify 
      articles that referred to the use of a combination of SSRIs and PDE-5 inhibitors 
      for the treatment of PE. A meta-analysis of these clinical studies was performed. 
      The post-treatment intravaginal ejaculatory latency time (IELT) and adverse 
      events (AEs) were used in this meta-analysis. RESULTS: Six publications involving 
      971 patients were included in the meta-analysis. In the analysis, we found 
      significantly improved IELT in the combination use group compared with the use of 
      SSRIs (mean differences [MD], 1.01; 95% confidence interval [CI], 0.61-1.41; P 
      <.01) or PDE-5 inhibitors alone (MD, 1.11; 95% CI, 0.79-1.43; P <.01) for PE 
      whether or not these patients suffered from erectile dysfunction. Combined 
      treatment was more efficacious than use of PDE-5 inhibitors alone on sexual 
      satisfaction. Although the occurrence of drug-related AEs in the combination use 
      group was higher than that in the use of SSRIs or PDE-5 inhibitors alone group 
      (37.5% vs 25.63%, P <.01), the most common AEs were mild and tolerable. 
      CONCLUSION: The combined use of SSRIs and PDE-5 inhibitors provided additive 
      favorable effects in men with PE compared with SSRIs or PDE-5 inhibitors 
      monotherapy and was generally well tolerated.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Bai, Yunjin
AU  - Bai Y
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Pu, Chunxiao
AU  - Pu C
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Han, Ping
AU  - Han P
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, China. 
      Electronic address: hanpinghxyy@163.com.
FAU - Li, Jinhong
AU  - Li J
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Yuan, Haichao
AU  - Yuan H
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, China; 
      Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 
      Province, China.
FAU - Tang, Yin
AU  - Tang Y
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Wang, Xiaoming
AU  - Wang X
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Wei, Qiang
AU  - Wei Q
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20150803
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - EC 3.1.4.35 (Cyclic Nucleotide Phosphodiesterases, Type 5)
SB  - IM
CIN - Urology. 2015 Oct;86(4):765. PMID: 26343234
CIN - Urology. 2015 Oct;86(4):764-5. PMID: 26343237
MH  - Cyclic Nucleotide Phosphodiesterases, Type 5/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Ejaculation/*drug effects
MH  - Humans
MH  - Male
MH  - Premature Ejaculation/*drug therapy/physiopathology
MH  - Selective Serotonin Reuptake Inhibitors/*therapeutic use
MH  - Treatment Outcome
EDAT- 2015/08/08 06:00
MHDA- 2016/01/06 06:00
CRDT- 2015/08/07 06:00
PHST- 2015/04/03 00:00 [received]
PHST- 2015/06/14 00:00 [revised]
PHST- 2015/06/16 00:00 [accepted]
PHST- 2015/08/07 06:00 [entrez]
PHST- 2015/08/08 06:00 [pubmed]
PHST- 2016/01/06 06:00 [medline]
AID - S0090-4295(15)00709-8 [pii]
AID - 10.1016/j.urology.2015.06.045 [doi]
PST - ppublish
SO  - Urology. 2015 Oct;86(4):758-64. doi: 10.1016/j.urology.2015.06.045. Epub 2015 Aug 
      3.